Efficasy of Rohitak Lauha in management of Non alcoholic fatty liver (NAFLD)

A Clinical trail to Evaluate the efficacy of Rohitaka Lauha in the management of Yakrit Vikara w.s.r.t. Non alcoholoc fatty liver disease (NAFLD) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/091548

Enrollment

110

Registered

2025-07-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E788- Other disorders of lipoprotein metabolism Health Condition 2: E788- Other disorders of lipoprotein metabolism

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having Grade 1 to Grade 2 Fatty Liver changes on USG report. 2. Patients having NAFLD score -1.455 to 0.675. 3. Patient irrespective of sex, Caste and Religion.

Exclusion criteria

Exclusion criteria: 1. Patients having more than Grade 3 A Fatty Liver on USG report. 2. Patients having NAFLD score more than 0.675. 3. Patients having any other metabolic disorders, malignancies, auto-immune disorders or life-threatening disorders Pregnant and lactating woman Patients with a previously established diagnosis of chronic disease including congestive heart failure, decompensated or severe lung disease, neoplasms, kidney disease, carriers of the human immunodeficiency virus (HIV), and advanced chronic liver diseases (Child-Pugh classification B and C) caused by any causal agent unrelated to NAFLD Recreational drug users; Patients with an average intake of more than 20 g of alcohol per day and or a history of alcoholic disease in abstention for less than 6 months Patients on prescribed medication including steroids, oestrogens, amiodarone, warfarin, anticonvulsants, antipsychotics, or chemotherapy drugs in the past 6 months Patients having history of infections, surgery, trauma, or hospitalization in the past 30 days Patients of chronic degenerative diseases of non-hepatic origin

Design outcomes

Primary

Measure	Time frame
Rohitak Lauh will reverse the changes of NAFLD (Non-Alcoholic Fatty Liver Disorder) in NAFLD SCORETimepoint: 45 days	—

Secondary

Measure	Time frame
As secondary objectives, the following will be assessed: Body mass index (BMI) and waist circumference (WC) Glucose metabolism biomarkers including blood glucose and glycated haemoglobin (HbA1c) Blood ferritin levels Biomarkers of liver damage, including transaminases, gamma-glutamyl transferase (GGT), and alkaline phosphatase (AP)Timepoint: 45 days	—

Countries

India

Contacts

Public ContactVaidya Rakesh Sharma

NCISM, New delhi

president.berism@ncismindia.org9814779242

Outcome results